Core Viewpoint - Emerging Growth Research reaffirms a Buy-Emerging rating for OSR Holdings, Inc. with a 12-month price target of $10.00, indicating a potential upside of approximately 1,487% from the closing price of $0.63 on December 3, 2025 [2][3]. Licensing Agreement - OSR Holdings has announced a major non-binding licensing term sheet with BCM Europe AG valued at $815 million for the global development and commercialization of VXM01, an oral T-cell immunotherapy program [3][6]. - The agreement includes an initial upfront payment of $20 million expected in 2026, along with significant milestone payments [6]. Strategic Implications - The licensing agreement is seen as a significant milestone for OSR Holdings, validating the management's strategic vision and execution capabilities [3][6]. - The likelihood of completing a definitive licensing agreement has increased due to BCME's formation of a fund structure and accelerated exclusivity timelines [6]. Financial Outlook - The licensing deal is expected to generate meaningful cash flow starting in 2026, addressing previous investor concerns regarding cash burn and share dilution [6]. - The potential expansion of the BCME partnership to include additional oncology assets could provide further valuation upside through a multi-asset licensing structure [6]. Market Recovery - OSR Holdings shares have recovered from early 2025 lows caused by market maker disputes and other issues unrelated to the company's fundamentals, but they remain heavily discounted relative to their intrinsic value [6].

Core Viewpoint - Vaxil Bio Ltd. has successfully completed a non-brokered private placement, raising gross proceeds of $140,000, which will be used to explore strategic options beyond the healthcare sector to maximize shareholder value [2][4]. Group 1: Private Placement Details - The private placement involved the subscription of 1,244,441 units at a price of $0.1125 per unit, with each unit consisting of one common share and one warrant [2]. - Each warrant is exercisable at an exercise price of $0.15 per warrant share until December 2, 2030 [2]. - The company compensated finders with fees totaling $11,200 and issued 99,555 finders' warrants with terms identical to the warrants issued in the private placement [3]. Group 2: Management Changes - Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Board of Directors, effective immediately [4]. - Mr. Simon Igelman has been appointed to the Board, bringing expertise in corporate finance and mergers and acquisitions [4][5]. - The Chairman of Vaxil expressed gratitude to the departing directors and welcomed Mr. Igelman, indicating a focus on pursuing new strategic opportunities [6]. Group 3: Company Background - Vaxil was previously focused on immunotherapy, particularly its lead product ImMucin™, which received orphan drug status from the FDA and EMA [7]. - The company is currently evaluating opportunities outside the biotechnology sector to enhance shareholder value [4][7].

Core Viewpoint - Greenwich LifeSciences, Inc. is making significant progress in its Phase III clinical trial, FLAMINGO-01, aimed at evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences [1][2]. Group 1: FLAMINGO-01 Progress - The company has screened over 1,000 patients in the FLAMINGO-01 trial, maintaining a screening rate of approximately 150 patients per quarter, equating to 600 patients annually across 140 active sites [2][3]. - The company is considering a strategy to continue enrolling patients in both HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted [2]. Group 2: Clinical Trial Details - FLAMINGO-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients who have residual disease or high-risk pathologic complete response after surgery [4]. - The trial will randomize approximately 500 HLA-A*02 patients to receive either GLSI-100 or a placebo, with an additional arm for up to 250 patients of other HLA types [4]. - An interim analysis for superiority and futility will be conducted after at least 14 events have occurred, with the trial designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival [4]. Group 3: Company Overview - Greenwich LifeSciences is focused on developing GP2, an immunotherapy aimed at preventing breast cancer recurrences in patients post-surgery [6]. - The company is actively expanding its clinical trial sites, with plans to open up to 150 sites globally [4].

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Pioneering protease-based masking of therapeutic antibodies and biologics, particularly in oncology Key Points Colorectal Cancer Data - **Product**: CX2051, an antibody-drug conjugate (ADC) targeting EpCAM, specifically designed for late-line colorectal cancer (CRC) treatment [2][3] - **Phase 1 Data**: Initial data showed a 28% confirmed response rate in late-stage CRC patients with a median of four prior therapies [4][10] - **Patient Enrollment**: Expanded from 25 to 100 patients in the phase 1 study, with a focus on evaluating 73 to 100 patients for efficacy [5][10] Dose Escalation and Safety - **Dose Levels**: Current doses being evaluated are 7.2, 8.6, and 10 mg/kg, with no dose-limiting toxicities (DLTs) reported to date [9][10] - **Response Rate Expectations**: Current treatment options for late-stage CRC have low response rates; CytomX aims to demonstrate superior efficacy with CX2051 [10][11] Future Development Plans - **Next Steps**: Plans to initiate a combination study with bevacizumab (Bev) in Q1 2026, and potentially a registrational study in the fourth line of therapy against fruquintinib [13][14] - **Additional Indications**: Exploring the use of CX2051 in other solid tumors, including gastric and pancreatic cancers, as EpCAM is highly expressed in these types [15] Competitive Landscape - **Market Position**: CX2051 is the first anti-EpCAM ADC developed, with other competitors in the topo-based ADC space showing promise but not matching the initial data from CytomX [18][20] Other Programs - **CX-801 Program**: A masked interferon alpha-2b designed to enhance the immune response while minimizing systemic side effects, with plans for combination studies with Keytruda in late-stage melanoma [21][22] - **Therapeutic Window**: The goal is to improve tolerability and efficacy of established therapies through innovative masking technology [23] Data Presentation - **Upcoming Data Reveal**: Anticipated updates on the 100 patient study in Q1 2026, with a focus on determining optimal dosing and safety profiles [25][26] Conclusion CytomX Therapeutics is positioned to make significant advancements in the treatment of colorectal cancer and other solid tumors through its innovative ADC technology and strategic development plans. The company is actively expanding its clinical trials and exploring new indications, while maintaining a competitive edge in the oncology market.

Bio-Techne (NasdaqGS:TECH) FY Conference December 02, 2025 08:20 AM ET Company ParticipantsDaniel Markowitz - Equity Research AssociateChuck Kummeth - CEOJames Hippel - CFOJames HippelThank you both for being with us.Chuck KummethYeah, James, thanks for having us. Especially first thing after the turkey hangover.Daniel MarkowitzTurkey hangover. Starting off sort of high level on the one Q overview, you posted an organic decline of 1%. Can you just give us a quick overview of the quarter and, I guess, the ma ...

Core Points - CERo Therapeutics Holdings, Inc. will trade on the OTCQB market under the ticker symbol CERO effective December 2, 2025 [2] - The company is exploring options for an up-list to a major exchange to enhance liquidity and investor accessibility [2] - CERo is focused on advancing its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML), with a significant increase in starting dosage compared to previous cohorts [3] - CERo's proprietary T cell engineering approach integrates innate and adaptive immunity to target tumors more effectively, potentially offering advantages over existing CAR-T therapies [4] - The company has initiated clinical trials for its lead product candidate, CER-1236, aimed at treating hematologic malignancies [4]

Core Insights - BriaCell Therapeutics Corp. is set to present positive Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, highlighting the potential of their novel immunotherapies in cancer treatment [1][7] Group 1: Presentation Details - The company will present three posters, including a pivotal Phase 3 trial analysis involving 116 patients, which shows an excellent safety profile and improved progression-free survival (PFS) in specific breast cancer subtypes [3][7] - A Phase II study on the Bria-IMT regimen combined with an anti-PD-1 checkpoint inhibitor demonstrated continued overall survival benefits in 54 metastatic breast cancer patients [4] - Analysis of blood cytokines from 30 patients suggests that Th1 biased cytokines may serve as predictive biomarkers for clinical responses to the Bria-IMT regimen [5] Group 2: Company Statements - The President & CEO of BriaCell expressed optimism about the survival and biomarker data, emphasizing the commitment to improving outcomes for cancer patients with unmet medical needs [2] - The Chief Medical Officer highlighted the significance of biomarker and patient subgroup data in identifying patients likely to benefit from their treatment [2]

Immutep Overview - Immutep has approximately A$109.85 million in cash and cash equivalents, providing a runway to the end of CY2026[14] - Immutep is developing four clinical-stage assets, including eftilagimod alfa (efti) and IMP761, designed to empower the immune system to fight cancer and autoimmune diseases[14] TACTI-004 (KEYNOTE-F91) Phase III Trial - The NSCLC drug market is expected to reach US$48 billion in sales in 2031[14,24] - The TACTI-004 Phase III trial has activated over 100 clinical sites across 24 countries and enrolled over 170 patients as of October 2025[25,30] - MSD is supplying KEYTRUDA for the TACTI-004 trial, with a typical ICI supply value of approximately US$100 million[30,32] Efficacy and Safety - In the INSIGHT-003 trial, a 62.7% objective response rate and a 90.2% disease control rate were observed across all PD-L1 expression levels in first-line NSCLC patients[52] - The EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint, demonstrating a median 51.5% tumor hyalinization/fibrosis rate (p<0.001) with neoadjuvant efti + KEYTRUDA + radiotherapy[52,70] Financials - Immutep's total revenue and other income were A$10.3 million in FY25, compared to A$7.8 million in FY24[79,80] - Research and development and intellectual property expenses increased to A$61.4 million in FY25[79,80] - The company reported a net loss of A$61.4 million in FY25[79] Intellectual Property - In FY24, seven patents were granted for efti, including six patents for efti in combination with a PD-1 pathway inhibitor[84] - Seven patents were granted for IMP761 in FY24[84] Anti-PD-(L)1 Therapies Sales - KEYTRUDA sales were approximately $29.5 billion in 2024[50,51] - OPDIVO sales were approximately $9.3 billion in 2024[50,51]

Core Insights - Sun Pharmaceutical Industries Limited announced FDA approval for an updated label for UNLOXCYT (cosibelimab-ipdl) for adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation [1][5][14] - The updated label includes long-term follow-up data from the pivotal CK-301-101 trial, demonstrating durable clinical responses in patients treated with UNLOXCYT [1][6] Efficacy Data - In the CK-301-101 trial, at least 50% of patients achieved the primary endpoint of objective response, with 14% of mCSCC patients and 32% of laCSCC patients achieving stable disease [2][6] - The median duration of response was not reached for either group at the time of follow-up analysis, indicating sustained efficacy [2][6] - The objective response rate (ORR) was 50% for mCSCC and 55% for laCSCC, with complete responses observed in 13% and 26% of patients, respectively [8] Safety Profile - The most common adverse reactions (≥10%) included fatigue, musculoskeletal pain, rash, diarrhea, and hypothyroidism, with 24% of patients experiencing immune-mediated adverse reactions (imARs) [3][21] - There were no treatment-related deaths reported, and the safety profile remained unchanged with the updated label [6][10] Mechanism of Action - UNLOXCYT works by restoring the adaptive immune response, inhibiting PD-L1 binding to PD-1 on T cells, and engaging the innate immune system through binding to natural killer (NK) cells [4][6] Market Context - CSCC is the second most common type of skin cancer in the U.S., with approximately 1 million diagnoses annually, and around 40,000 cases progress to advanced stages each year [9][10] - UNLOXCYT is the first and only PD-L1 immune checkpoint inhibitor approved for advanced CSCC, addressing a significant unmet need for durable and tolerable treatment options [6][10] Future Plans - Sun Pharma plans to commercially launch UNLOXCYT in early 2026, reinforcing its commitment to advancing innovative treatment options in cutaneous oncology [5][10]

Core Points - BioVaxys Technology Corp. has issued 1,792,387 common shares at a deemed value of $0.23 per share to settle an outstanding debt of $412,249 [1][2] Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada, focused on developing novel immunotherapies using the DPX™ immune-educating technology platform and the HapTenix© tumor cell construct platform [4] - The company's clinical pipeline includes maveropepimut-S (MVP-S), which is in Phase IIB development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer [4] - MVP-S targets survivin, a cancer antigen, and has shown clinical benefits and activation of a survivin-specific anti-tumor immune response [4] - BioVaxys is also developing other therapies, including DPX™+SurMAGE for dual-targeted immunotherapy, DPX™-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized immunotherapeutic vaccine for late-stage ovarian cancer [4] Securities Information - BioVaxys common shares are listed on the Canadian Securities Exchange (CSE) under the symbol "BIOV" and also trade on the Frankfurt Bourse and OTC Markets [5]